Search the Newsreel

BlackRock Inc (BPRN) discloses 5.5% Princeton Bancorp ownership with sole control

BlackRock, Inc. has disclosed a beneficial ownership of 5.5% in Princeton Bancorp Inc (BPRN), holding 374,815 shares of common stock. The firm asserts sole voting power over 369,803 shares and sole dispositive power over all 374,815 shares. This disclosure, filed as a Schedule 13G, …

Eton seeks FDA expansion of hydrocortisone liquid for children under 5

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the label of its KHINDIVI oral solution to include pediatric adrenal insufficiency patients under five years old. A new formulation of KHINDIVI demonstrated bioequivalence to an FDA-approved hydrocortisone granule formulation, potentially …

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI (hydrocortisone) oral solution to include younger pediatric patients. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, and the company anticipates potential approval in the first half of …

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High - What's Next?

Eton Pharmaceuticals (NASDAQ:ETON) recently hit a new 52-week high of $45.27, trading near $44.91, following a consensus "Moderate Buy" rating and an average price target of $52.50 from analysts. Despite beating revenue expectations, the company missed EPS estimates in its latest quarter, and insiders …

EcoR1 Capital LLC Purchases 141,394 Shares of Eton Pharmaceuticals, Inc. $ETON

EcoR1 Capital LLC has increased its stake in Eton Pharmaceuticals (NASDAQ:ETON) by 7%, purchasing an additional 141,394 shares to own 7.93% of the company, valued at approximately $53.6 million. Despite a "Moderate Buy" consensus rating and a $45.75 target price from analysts, company insiders …

BlackRock (ETON stakeholder) reports 6.9% ownership in Eton Pharmaceuticals common stock

BlackRock, Inc. has filed an amended Schedule 13G/A report indicating a beneficial ownership of 1,882,410 shares of Eton Pharmaceuticals, Inc. common stock, which represents 6.9% of the outstanding class as of June 30, 2026. The filing shows BlackRock holds sole voting power over 1,850,186 …

Eton Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ETON

This article provides a revenue breakdown for Eton Pharmaceuticals Inc (ETON), focusing on its business segments and regional contributions. It notes that relevant data for FY2025 and its quarters, as well as FY2024, have not yet been disclosed by the company. However, it does …

ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock?

Shares of Eton Pharmaceuticals Inc (ETON) jumped 10% after Craig-Hallum raised its price target to $62 from $40, maintaining a 'Buy' rating. The firm's optimism stems from new products like Amglidia and an acquired generic drug application, alongside more positive sales projections for existing …

Princeton Bancorp Inc (BPRN) Financial Health: Profitability & Balance Sheet Analysis

Princeton Bancorp Inc (BPRN) currently holds a financial score of 5.11, positioning it robustly in the Banking Services industry despite low operating efficiency. The company reported a significant year-over-year revenue increase of 8.49% to $20.18M and a remarkable 929.22% surge in net profit during …

Eton Pharmaceuticals Inc (ETON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Eton Pharmaceuticals Inc (ETON), focusing on its business segments and regional contributions. It notes that relevant data for FY2025 and its quarters, as well as FY2024, have not yet been disclosed by the company. However, it does …

Systematic Financial Management LP Trims Stock Position in Princeton Bancorp, Inc. $BPRN

Systematic Financial Management LP reduced its stake in Princeton Bancorp, Inc. (NASDAQ:BPRN) by 22.9% in the first quarter, now owning 238,887 shares. Other institutional investors like Dimensional Fund Advisors LP, Quadrature Capital Ltd, Millennium Management LLC, First Manhattan CO. LLC., and AQR Capital Management …

BPRN|Princeton Bancorp Inc|Price:40.790|Chg%:-0.065

Princeton Bancorp Inc (BPRN) has healthy fundamentals and high growth potential but is considered fairly valued. Despite recent positive stock performance, underlying fundamentals and technicals are weak, indicating a sideways trading pattern between support and resistance levels. The company is in a growing phase, …

Princeton Bancorp Inc (BPRN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Princeton Bancorp Inc (BPRN), listing both major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key entities. The content …

ETON|Eton Pharmaceuticals Inc|Price:42.590|Chg%:-1.550

This article provides a financial overview of Eton Pharmaceuticals Inc. (ETON), detailing its stock performance, key financial indicators like EPS and revenue, and trends in its income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings release, revenue growth, and …

Eton Pharmaceuticals (ETON) Short Interest & Short Float | Updated Jul 2026

Eton Pharmaceuticals (ETON) reported a short interest of 1.23 million shares as of July 15, 2026, representing 5.36% of its public float, which is a 15.40% decrease from the previous report. The short interest ratio stands at 3.0 days to cover. The article provides …

The Technical Signals Behind (ETON) That Institutions Follow

This article analyzes Eton Pharmaceuticals Inc. (NASDAQ: ETON) based on AI-generated technical signals, indicating strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents specific institutional trading strategies, including position trading, momentum …

BPRN Reports Strong Q2 Performance with Increased Net Interest I

Princeton Bancorp Inc (BPRN) reported strong financial results for Q2 2026, with net interest income reaching $20.0 million and diluted earnings per share of $1.04. The company's net interest margin improved to 3.86%, contributing to a moderate GF Score™ of 65/100, indicating potential for …

Princeton Bancorp (BPRN) Q2 2026 earnings summary

Princeton Bancorp (BPRN) reported a strong Q2 2026 with net income rising to $7.1 million ($1.04 per diluted share), a significant increase from both the previous quarter and the same period last year. The performance was driven by higher net interest income, improved net …

Princeton Bancorp Q2 FY26 net income rises 14.52% to $7.1 million; net interest income climbs 6% to $20 million

Princeton Bancorp reported a Q2 FY26 net income of $7.1 million, a 14.52% increase from the previous quarter, with diluted EPS rising to $1.04. Net interest income grew by 6% to $20 million, and the net interest margin expanded to 3.86%. CEO Edward Dietzler …

Princeton Bancorp: Q2 Earnings Snapshot

Princeton Bancorp (BPRN) reported a net income of $7.1 million, or $1.04 per share, in its second quarter. The bank's revenue, net of interest expense, reached $22.5 million, exceeding Street forecasts. Shares of Princeton Bancorp have seen a 7% increase since the beginning of …

Eton Pharmaceuticals stock hits all-time high at 44.0 USD By Investing.com

Eton Pharmaceuticals (NASDAQ: ETON) stock reached an all-time high of $44.00, surpassing its 52-week high, despite InvestingPro analysis suggesting it is overvalued. The company has seen a 183.54% increase over the past year and analysts predict profitability for the current year. Recent developments include …

Princeton Bancorp (BPRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Princeton Bancorp (BPRN) Q2 Earnings and Revenues Beat Estimates

Princeton Bancorp (BPRN) reported Q2 earnings of $1.04 per share, significantly beating the Zacks Consensus Estimate of $0.9 per share and surpassing last year's earnings. The company also exceeded revenue expectations, posting $22.48 million against an estimated $21.84 million. Despite outperforming expectations, the stock …

Wijaya Karya (WIKA) Buka Suara Terkait Potensi Delisting dari Bursa

Princeton Bancorp Keeps Quarterly Dividend at $0.35 per Share, Payable Aug. 28 to Holders of Record Aug. 5

Princeton Bancorp (NASDAQ: BPRN) has declared a quarterly cash dividend of $0.35 per share, maintaining its previous payout. The dividend is scheduled to be paid on August 28 to shareholders who are on record as of August 5. This announcement confirms the bank's consistent …

Eton Pharmaceuticals Inc. (ETON) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Eton Pharmaceuticals Inc. (ETON) stock, showing its current price as $43.20, up by 2.11%. The article also mentions that there are no analyst ratings or earnings information currently available for ETON. It includes promotional material common …

Princeton Bancorp Sets Aug. 28 Payment for $0.35 Dividend

Princeton Bancorp, Inc. (NASDAQ: BPRN) announced a quarterly cash dividend of $0.35 per share, payable on August 28, 2026, to shareholders of record as of August 5, 2026. This decision, made by the Board of Directors on July 22, 2026, reflects the company's commitment …

Princeton Bancorp declares $0.35 quarterly dividend

Princeton Bancorp (NASDAQ:BPRN) announced that its Board of Directors has declared a cash dividend of $0.35 per share of common stock. This dividend will be paid on August 28, 2026, to shareholders recorded by August 5, 2026. The company stated this dividend reflects their …

Eton Pharmaceuticals (ETON) Gains On Rare Disease Momentum, Is It Still Undervalued?

Eton Pharmaceuticals (ETON) saw its stock climb 13.8% recently, contributing to a 33% 30-day return and a 165.68% year-to-date return, driven by its rare disease portfolio. While a fair value analysis suggests the stock is 5.4% undervalued at $43.20 compared to a $45.67 target, …

Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?

Eton Pharmaceuticals (ETON) saw its shares jump 13.8% due to investor confidence in its growth prospects, driven by strong commercial momentum from existing products and a promising late-stage pipeline. The company is expected to report significant quarterly earnings and revenue growth. However, Zacks maintains …

Opaleye management sells $1.06m in Eton Pharmaceuticals stock

Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals (NASDAQ:ETON), sold 28,315 shares of the company's common stock for over $1 million on July 14, 2026. Despite the sale, Eton shares have surged more than 200% in the past year and are trading near …

ETON Surges As Canaccord Sets Aggressive $60 Price Target

Eton Pharmaceuticals Inc. (ETON) stock surged by 13.61% after Canaccord Genuity initiated coverage with a "Buy" rating and an aggressive $60 price target, significantly higher than the previous analyst mean. This positive outlook is primarily driven by Eton's focus on ultra-rare pediatric diseases and …

Eton Pharmaceuticals, Inc. 4/A — Insider Transaction

The article reports an insider transaction (Form 4/A) for Eton Pharmaceuticals, Inc. filed on July 17, 2026. This filing is available for viewing on SEC.gov. The platform MLQ.ai provides this research, along with other data on companies, infrastructure, and frontier tech.

Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins

Despite a significant 13x return over the past three years and recent FDA approval, Eton Pharmaceuticals (ETON) appears overvalued according to Simply Wall St's analysis. The stock trades at a Price/Sales ratio of 13.3x, significantly higher than the industry average of 6.2x, suggesting that …

Form 4 Eton Pharmaceuticals Inc For: 17 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Eton Pharmaceuticals Inc. dated July 17. The brief piece includes the company's stock symbol (ETON) and its performance, showing a 13.79% increase. It serves as a standard financial news alert regarding insider transactions.

ETON Stock Pops As Canaccord Genuity Targets $60

Eton Pharmaceuticals (ETON) stock has risen by 13.61% after Canaccord Genuity initiated coverage with a Buy rating and a $60 price target. This analyst coverage, released on July 16, 2026, has led to a significant surge in trading volume and price action. The company …